4Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract
Introduction
More than one hundred years have passed since Felix Hoffman in 1897 synthesised acetylsalicylic acid (ASA) as the first non-steroidal anti-inflammatory drug. Approximately 40 years pass before Douthwaite and Lintott provided endoscopic evidence that aspirin could cause gastrointestinal injury and it is in the early 1970s when investigators began to understand how aspirin works by showing that ASA inhibits the production of prostaglandins, that are involved in inflammations.
Today, NSAIDs are among the most commonly used drugs in the world. In Europe, NSAIDs represents more than 7.7% of all prescriptions and it is probably that these figures are underestimated because of over-the-counter use is not included [1]. In absolute terms, in the year 2004, a total of 111 million NSAID prescriptions were written in the United States [2], and it is expected that the use of NSAIDs will increase because the incidence of rheumatic diseases also is increasing. Their use is more frequent among women and increases with age, as does the incidence of rheumatic diseases. Indeed more than 90% of prescriptions for NSAIDs are made to patients aged >65 years.
The major problem with the use of these drugs is that adverse events are common, especially gastrointestinal morbidities, including complications in both upper and lower gastrointestinal tract.
Section snippets
Mechanisms of gastrointestinal (GI) injury
NSAIDs injure the gut by causing topical injury to the mucosa and a systemic effects associated with mucosal prostaglandin depletion derived from COX-1. The systemic effects of NSAIDs appear to have the predominant role. Because of that the use of enteric-coated aspirin preparations and parenteral or rectal administration of NSAIDs in order to prevent topical mucosal injury has failed to prevent the development of ulcers.
Upper gastrointestinal effects of NSAIDs
NSAIDs can adversely affect both the upper and lower gastrointestinal tract. The clinical significance and frequency of adverse events with NSAIDs in the lower GI tract have been increasingly reported, but are less characterised than those from the upper GI tract. A recent study from Lanas et al [8] have shown that the frequency of hospitalisations due to upper GI complications decreasing for the last 10 years, whereas those from the lower GI tract are increasing. In this article, we will focus
The role of cyclooxygenase 2 inhibitors
The identification of the COX-2 isoenzyme opened the door to development of NSAIDs which selectively inhibit COX-2. The main goal of which was to decrease the GI toxicity. Coxib spare COX-1 and primarily inhibit COX-2 function therefore decrease but do not eliminate NSAIDs associated GI toxicity and are efficacious as tNSAIDs in relieving pain [15].
Data from large GI outcomes studies have characterised the GI effects of coxib. The Celecoxib Long-term Arthritis Safety Study (CLASS Study) that
Risk factors for gastrointestinal complications
Dyspeptic symptoms are not a trustworthy warming sign; because of that it is important to identify factors that increase the risk of GI events in NSAIDs users. Several studies have demonstrated which are the major risk factors for GI event associated with NSAID therapy. (Table 1) [50], [51], [52], [23].
Among them, the two main are prior history of complicated ulcers, the most important one, and age. Older age is the most common in NSAIDs users and those age >70 years are considered to carry a
Management
The main goal in the management of patients receiving NSAIDS is the prevention of GI complications. Other objectives are the treatment of GI mucosal lesions and the treatment and prevention of NSAID-induced dyspepsia. Finally, due to the association of NSAID and coxib use with CV risk, this factor should also be taken into account in the management of patients who need NSAIDs.
Conflict of interest
Dr Angel Lanas is consultant or has received research grants from AstraZeneca, Pfizer, Bayer and Nicox. Dr Carlos Sostres, Dr Carla J. Gargallo and Dr María T. Arroyo reports no conflict of interest.
Acknowledgements
This study was funded by grants from the Carlos III, FIS PI08/1301 and Gobierno de Aragón. B01
References (85)
- et al.
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage
Am J Med
(1989) NSAIDs, gastrointestinal injury, and cytoprotection
Gastroenterol Clin North Am
(1996)- et al.
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2
Gastroenterology
(2000) - et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Lancet
(2004) - et al.
Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection
Clin Gastroenterol Hepatol
(2005) - et al.
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study
Am J Med
(2006) - et al.
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial
Gastroenterology
(2004) - et al.
MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomized comparison
Lancet
(2006 Nov 18) - et al.
MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomized comparison
Lancet
(2007 Feb 10) - et al.
Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis
Am J Cardiol
(2009 Sep 15)